GlaxoSmithKline PLC — Director's Dealing 2017

Oct 25, 2017

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION

Washington D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of

the Securities Exchange Act of 1934

For period ending 25 October 2017

GlaxoSmithKline plc

(Name of registrant)

980 Great West Road, Brentford, Middlesex, TW8 9GS

(Address of principal executive offices)

Indicate by check mark whether the registrant files or

will file annual reports under cover Form 20-F or Form 40-F

Form 20-F x Form 40-F

--

Indicate by check mark whether the registrant by furnishing the

information contained in this Form is also thereby furnishing the

information to the Commission pursuant to Rule 12g3-2(b) under the

Securities Exchange Act of 1934.

Yes No x

GlaxoSmithKline plc (the ' Company ')

Transaction notification

| 1. — a) | Details of PDMR/person closely associated with them
('PCA') — Name | Philip Hampton | |
| --- | --- | --- | --- |
| b) | Position/status | Non-Executive Chairman | |
| c) | Initial
notification/ amendment | Initial notification | |
| 2. | Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor | | |
| a) | Name | GlaxoSmithKline plc | |
| b) | LEI | 5493000HZTVUYLO1D793 | |
| 3. | Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted | | |
| a) | Description of
the financial instrument | Ordinary shares of 25 pence each ('Ordinary Shares') ISIN:
GB0009252882 | |
| b) | Nature of the
transaction | Acquisition of notional Ordinary Shares under the share allocation
arrangements for Independent Non-Executive Directors for the period
of service from 1 July 2017 to 30 September 2017. | |
| c) | Price(s) and volume(s) | Price(s) | Volume(s) |
| | | £15.18 | 2,882.082 |
| d) | Aggregated
information Aggregated
volume Price | n/a (single transaction) | |
| e) | Date
of the transaction | 2017-10-25 | |
| f) | Place
of the transaction | n/a | |

| 1. — a) | Details of PDMR/person closely associated with them
('PCA') — Name | Professor Sir Roy Anderson | |
| --- | --- | --- | --- |
| b) | Position/status | Independent Non-Executive Director | |
| c) | Initial
notification/ amendment | Initial notification | |
| 2. | Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor | | |
| a) | Name | GlaxoSmithKline plc | |
| b) | LEI | 5493000HZTVUYLO1D793 | |
| 3. | Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted | | |
| a) | Description of
the financial instrument | Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882 | |
| b) | Nature of the
transaction | Acquisition of notional Ordinary Shares under the share allocation
arrangements for Independent Non-Executive Directors for the period
of service from 1 July 2017 to 30 September 2017. | |
| c) | Price(s)
and volume(s) | Price(s) | Volume(s) |
| | | £15.18 | 473.485 |
| d) | Aggregated
information Aggregated
volume Price | n/a (single transaction) | |
| e) | Date
of the transaction | 2017-10-25 | |
| f) | Place
of the transaction | n/a | |

| 1. — a) | Details of PDMR/person closely associated with them
('PCA') — Name | Mr Vindi Banga | |
| --- | --- | --- | --- |
| b) | Position/status | Senior Independent Non-Executive Director | |
| c) | Initial
notification/ amendment | Initial notification | |
| 2. | Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor | | |
| a) | Name | GlaxoSmithKline plc | |
| b) | LEI | 5493000HZTVUYLO1D793 | |
| 3. | Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted | | |
| a) | Description of
the financial instrument | Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882 | |
| b) | Nature of the
transaction | Acquisition of notional Ordinary Shares under the share allocation
arrangements for Independent Non-Executive Directors for the period
of service from 1 July 2017 to 30 September 2017. | |
| c) | Price(s)
and volume(s) | Price(s) | Volume(s) |
| | | £15.18 | 1,893.939 |
| d) | Aggregated
information Aggregated
volume Price | n/a (single transaction) | |
| e) | Date
of the transaction | 2017-10-25 | |
| f) | Place
of the transaction | n/a | |

| 1. — a) | Details of PDMR/person closely associated with them
('PCA') — Name | Dr Vivienne Cox | |
| --- | --- | --- | --- |
| b) | Position/status | Independent Non-Executive Director | |
| c) | Initial
notification/ amendment | Initial notification | |
| 2. | Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor | | |
| a) | Name | GlaxoSmithKline plc | |
| b) | LEI | 5493000HZTVUYLO1D793 | |
| 3. | Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted | | |
| a) | Description of
the financial instrument | Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882 | |
| b) | Nature of the
transaction | Acquisition of notional Ordinary Shares under the share allocation
arrangements for Independent Non-Executive Directors for the period
of service from 1 July 2017 to 30 September 2017. | |
| c) | Price(s)
and volume(s) | Price(s) | Volume(s) |
| | | £15.18 | 349.967 |
| d) | Aggregated
information Aggregated
volume Price | n/a (single transaction) | |
| e) | Date
of the transaction | 2017-10-25 | |
| f) | Place
of the transaction | n/a | |

| 1. — a) | Details of PDMR/person closely associated with them
('PCA') — Name | Ms Lynn Elsenhans | |
| --- | --- | --- | --- |
| b) | Position/status | Independent Non-Executive Director | |
| c) | Initial
notification/ amendment | Initial notification | |
| 2. | Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor | | |
| a) | Name | GlaxoSmithKline plc | |
| b) | LEI | 5493000HZTVUYLO1D793 | |
| 3. | Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted | | |
| a) | Description of
the financial instrument | American Depositary Shares ('ADSs') ISIN: US37733W1053 | |
| b) | Nature of the
transaction | Acquisition of notional ADSs under the share allocation
arrangements for Independent Non-Executive Directors for the period
of service from 1 July 2017 to 30 September 2017. | |
| c) | Price(s)
and volume(s) | Price(s) | Volume(s) |
| | | $40.65 | 1,217.117 |
| d) | Aggregated
information Aggregated
volume Price | n/a (single transaction) | |
| e) | Date
of the transaction | 2017-10-25 | |
| f) | Place
of the transaction | n/a | |

| 1. — a) | Details of PDMR/person closely associated with them
('PCA') — Name | Dr Laurie Glimcher | |
| --- | --- | --- | --- |
| b) | Position/status | Independent Non-Executive Director | |
| c) | Initial
notification/ amendment | Initial notification | |
| 2. | Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor | | |
| a) | Name | GlaxoSmithKline plc | |
| b) | LEI | 5493000HZTVUYLO1D793 | |
| 3. | Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted | | |
| a) | Description of
the financial instrument | American Depositary Shares ('ADSs') ISIN: US37733W1053 | |
| b) | Nature of the
transaction | Acquisition of notional ADSs under the share allocation
arrangements for Independent Non-Executive Directors for the period
of service from 1 September 2017 to 30 September 2017. | |
| c) | Price(s)
and volume(s) | Price(s) | Volume(s) |
| | | $40.65 | 349.746 |
| d) | Aggregated
information Aggregated
volume Price | n/a (single transaction) | |
| e) | Date
of the transaction | 2017-10-25 | |
| f) | Place
of the transaction | n/a | |

| 1. — a) | Details of PDMR/person closely associated with them
('PCA') — Name | Dr Jesse Goodman | |
| --- | --- | --- | --- |
| b) | Position/status | Independent Non-Executive Director | |
| c) | Initial
notification/ amendment | Initial notification | |
| 2. | Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor | | |
| a) | Name | GlaxoSmithKline plc | |
| b) | LEI | 5493000HZTVUYLO1D793 | |
| 3. | Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted | | |
| a) | Description of
the financial instrument | American Depositary Shares ('ADSs') ISIN: US37733W1053 | |
| b) | Nature of the
transaction | Acquisition of notional ADSs under the share allocation
arrangements for Independent Non-Executive Directors for the period
of service from 1 July 2017 to 30 September 2017. | |
| c) | Price(s)
and v olume(s) | Price(s) | Volume(s) |
| | | $40.65 | 477.987 |
| d) | Aggregated
information Aggregated
volume Price | n/a (single transaction) | |
| e) | Date
of the transaction | 2017-10-25 | |
| f) | Place
of the transaction | n/a | |

| 1. — a) | Details of PDMR/person closely associated with them
('PCA') — Name | Ms Judy Lewent | |
| --- | --- | --- | --- |
| b) | Position/status | Independent Non-Executive Director | |
| c) | Initial
notification/ amendment | Initial notification | |
| 2. | Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor | | |
| a) | Name | GlaxoSmithKline plc | |
| b) | LEI | 5493000HZTVUYLO1D793 | |
| 3. | Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted | | |
| a) | Description of
the financial instrument | American Depositary Shares ('ADSs') ISIN: US37733W1053 | |
| b) | Nature of the
transaction | Acquisition of notional ADSs under the share allocation
arrangements for Independent Non-Executive Directors for the period
of service from 1 July 2017 to 30 September 2017. | |
| c) | Price(s)
and volume(s) | Price(s) | Volume(s) |
| | | $40.65 | 524.620 |
| d) | Aggregated
information Aggregated
volume Price | n/a (single transaction) | |
| e) | Date
of the transaction | 2017-10-25 | |
| f) | Place
of the transaction | n/a | |

| 1. — a) | Details of PDMR/person closely associated with them
('PCA') — Name | Mr Urs Rohner | |
| --- | --- | --- | --- |
| b) | Position/status | Independent Non-Executive Director | |
| c) | Initial
notification/ amendment | Initial notification | |
| 2. | Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor | | |
| a) | Name | GlaxoSmithKline plc | |
| b) | LEI | 5493000HZTVUYLO1D793 | |
| 3. | Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted | | |
| a) | Description of
the financial instrument | Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882 | |
| b) | Nature of the
transaction | Acquisition of notional Ordinary Shares under the share allocation
arrangements for Independent Non-Executive Directors for the period
of service from 1 July 2017 to 30 September 2017. | |
| c) | Price(s)
and volume(s) | Price(s) | Volume(s) |
| | | £15.18 | 473.485 |
| d) | Aggregated
information Aggregated
volume Price | n/a (single transaction) | |
| e) | Date
of the transaction | 2017-10-25 | |
| f) | Place
of the transaction | n/a | |

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

(Registrant)
Date: October
25, 2017
By: VICTORIA
WHYTE
Victoria Whyte
Authorised
Signatory for and on
behalf
of GlaxoSmithKline plc

page break